Martingale Asset Management L P bought a new stake in Horizon Pharma PLC (NASDAQ:HZNP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 67,246 shares of the biopharmaceutical company’s stock, valued at approximately $799,000.

Several other large investors have also recently modified their holdings of HZNP. BlackRock Inc. boosted its holdings in shares of Horizon Pharma PLC by 68,479.5% in the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock valued at $196,001,000 after acquiring an additional 13,241,875 shares in the last quarter. William Blair Investment Management LLC purchased a new stake in shares of Horizon Pharma PLC in the second quarter valued at about $23,557,000. Highbridge Capital Management LLC boosted its holdings in shares of Horizon Pharma PLC by 128.2% in the first quarter. Highbridge Capital Management LLC now owns 1,545,169 shares of the biopharmaceutical company’s stock valued at $22,837,000 after acquiring an additional 867,927 shares in the last quarter. Janus Capital Management LLC boosted its holdings in shares of Horizon Pharma PLC by 19.4% in the first quarter. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company’s stock valued at $65,173,000 after acquiring an additional 717,643 shares in the last quarter. Finally, North Tide Capital LLC purchased a new stake in shares of Horizon Pharma PLC in the first quarter valued at about $10,238,000. 82.30% of the stock is currently owned by institutional investors and hedge funds.

Shares of Horizon Pharma PLC (NASDAQ:HZNP) opened at 12.32 on Monday. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $21.98. The stock’s market cap is $2.01 billion. The company’s 50-day moving average is $12.81 and its 200-day moving average is $12.94.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.29. The firm had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. Horizon Pharma PLC’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.56 EPS. On average, analysts expect that Horizon Pharma PLC will post $1.07 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/25/martingale-asset-management-l-p-buys-new-holdings-in-horizon-pharma-plc-hznp.html.

Several brokerages have recently weighed in on HZNP. UBS AG set a $16.00 target price on shares of Horizon Pharma PLC and gave the company a “buy” rating in a report on Wednesday, June 7th. Mizuho reaffirmed a “neutral” rating and issued a $9.00 target price (down previously from $10.00) on shares of Horizon Pharma PLC in a report on Wednesday, August 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $18.00 target price (up previously from $17.00) on shares of Horizon Pharma PLC in a report on Thursday, August 10th. Zacks Investment Research raised shares of Horizon Pharma PLC from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $17.00 target price (up previously from $13.00) on shares of Horizon Pharma PLC in a report on Wednesday, August 9th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $18.67.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.